SPEAC Expert Dr Andy Stergachis awarded 1st place for poster for living systematic review of COVID-19 vaccine safety and pregnancy

at the annual conference of the International Society of Pharmacovigilance in Bali, Indonesia in November 2023

Dr. Andy Stergachis presented research on the safety, immunogenicity and effectiveness of COVID-19 vaccines for pregnant persons. Dr. Stergachis and team conducted a living systematic review and meta-analysis of nearly 600,000 pregnant persons who received COVID-19 vaccines. Read more

Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial

Batmunkh et al. in the Lancet Western Pacific

This CEPI funded COVID-19 study found that a half-dose of Pfizer-BioNTech's BNT162b2 boosting elicited an immune response that was non-inferior to a full-dose, with fewer reactions, in adults primed with Oxford-AstraZeneca's ChAdOx1 nCov-19 or Sinopharm's BBIBP-CorV Read more



SPEAC hosted this webinar on 22/09/23. The aim was to review what is known regarding SNHL, Lassa fever disease, & vaccines & to discuss how hearing abnormalities that may occur during clinical trials should be evaluated & monitored. Read more

Enable Lassa Research Programme Mid-term Workshop report

The Enable Lassa Research Programme is a prospective multi-site cohort study to estimate incidence of infection and disease due to Lassa fever virus, following 23,000 participants across five West African countries. To discuss the interim results of the Enable study ... Read more

CEPI exapnds partnership with The Brighton Collaboration

Safety Platform for Emergency Vaccines (SPEAC)

Renewed partnership will broaden the scope of SPEAC to deliver world-leading vaccine safety guidance & support for CEPI’s mission to compress development of new vaccines against pathogens with pandemic potential to 100 days Read more

Operational Preparedness Database Launched

CEPI has compiled COVID-19-specific national requirements and guidelines to conduct clinical trials in multiple countries across the globe, together with links to the respective regulatory authorities and ethics committees ... Read more

COVAX section launched on EPI hub

CEPI, alongside Gavi and the World Health Organisation, launched COVAX – the vaccines pillar of the ACT Accelerator – with the aim of ending the acute phase of the pandemic by the end of 2021... Read more

Clinical Trials Community Platform

The Clinical Trials Community is a platform of the African Academy of Sciences. Our goal is to increase the level of Clinical Trial investments in Africa by increasing the visibility of African clinical trialists and research sites as well as ... Read more